This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

- Training and Resources

Training and Resources

Oncology

Rating

Immunotherapy eLearning Module 1: Immunology Basics

Prescribing Information

Rating

Immunotherapy eLearning Module 2: The Immune System and Cancer

Developed by The Christie School of Oncology

Prescribing Information

Rating

KEYTRUDA®▼ (pembrolizumab) Mode of Action

Prescribing Information

General Itemtypeofcontent|therapeuticgroup|localproductname|otherother|Oncology|Keytruda|general133nulltcm:4244-556446Immunotherapy eLearning Module 1: Immunology Basics/static/mciuk/images/msdc_keytruda_immuno_basic@2x.png/training-resources/keytruda/elearning-1.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank">Prescribing Information</a>branded/static/mciuk/images/msdc_keytruda_immuno_basic@2x.pngassetIdtcm:4244-556446pathologieslocalproductnameKeytrudaglobalproductnameKeytrudakeywordsimmunology,immune system,immunotherapy,elearning,learning,pembrolizumab,keytruda,oncology,immuno-oncology,cancerspecialityexpirationdatepublicationdatecodextypeofcontenteCMEengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencetherapeuticgroupOncologyassettypeeCMEassetfranchiseOncologyasset_descriptionasset_purposeasset_content_classificationasset_accessibilityasset_publisherhashtagsreadtimetcm:4244-622887Immunotherapy eLearning Module 2: The Immune System and Cancer/static/mciuk/images/msdc_keytruda_immune_sys@2x.png/training-resources/keytruda/elearning-2.xhtml Developed by The Christie School of Oncology<a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank">Prescribing Information</a>branded/static/mciuk/images/msdc_keytruda_immune_sys@2x.pngassetIdtcm:4244-622887pathologieslocalproductnameKeytrudaglobalproductnameKeytrudakeywordsimmunology,immune system,immunotherapy,elearning,learning,pembrolizumab,keytruda,oncology,immuno-oncology,cancerspecialityexpirationdatepublicationdatecodextypeofcontenteCMEengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencetherapeuticgroupOncologyassettypeeCMEassetfranchiseOncologyasset_descriptionasset_purposeasset_content_classificationasset_accessibilityasset_publisherhashtagsreadtimetcm:4244-693520KEYTRUDA®▼ (pembrolizumab) Mode of Action/static/mciuk/images/keytruda_moa@2x.png/training-resources/keytruda/moa.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/keytruda_moa@2x.pngassetIdtcm:4244-693520pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsKeytruda,pembrolizumab,immontherapy,non small cell lung cancer,anti-Pd1,MOA,mode of action,mechanism of action,first line treatmentspecialityexpirationdatepublicationdate2018-11-06codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeProfessional Educationasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtags

Other resources

Oncology NSCLC resources

Prescribing Information

View Resources

Oncology Melanoma resources

Prescribing Information

View Resources

Oncology Urothelial Carcinoma resources

Prescribing Information

View Resources

Supporting documentation

KEYTRUDA^®▼ (pembrolizumab)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-PDO-00255 | Date of Preparation: February 2019